MarketPeel
Insider Trading Intelligence
DL

David Charles Lubner

ACLX
DIRECTOR · ARCELLX, INC. · CIK 0001572000
FILING MIX · LIFETIME65%/35%
BUYS
24
SELLS
13
TOTAL VALUE
$987.7K
COMPANIES
4
ACTIVE SINCE
Jul 2020
HOLDINGS NOW
76,202
AVG SELL PX
$75.00
TRADE KIND
SHOWING 37 / 37
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by David Charles Lubner, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%-5.07%+2.64%-7.71%-7.71%
14d1+100.00%-3.75%+1.76%-5.52%-5.52%
30d1+100.00%-7.82%+1.02%-8.83%-8.83%
60d1+0.00%+59.03%-4.28%+63.31%+63.31%
90d1+0.00%+59.35%+4.60%+54.75%+54.75%
180d1(1 pending)
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ACLX · 0 shares · as of Apr 28, 2026
015,38530,76946,15461,5382023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 24 buys / 13 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,15235,152Jun 5, 2026Jun 9, 2026View →
CBIO
CRESCENT BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
11,05011,050Jun 2, 2026Jun 3, 2026View →
ACLX
ARCELLX, INC.
SALE
59,4050Apr 28, 2026Apr 28, 2026View →
ACLX
ARCELLX, INC.
SALE
11,4590Apr 28, 2026Apr 28, 2026View →
ACLX
ARCELLX, INC.
SALE
61,5380Apr 28, 2026Apr 28, 2026View →
ACLX
ARCELLX, INC.
SALE
9,1740Apr 28, 2026Apr 28, 2026View →
ACLX
ARCELLX, INC.
SALE
21,6590Apr 28, 2026Apr 28, 2026View →
ACLX
ARCELLX, INC.
SALE
31,7940Apr 28, 2026Apr 28, 2026View →
ACLX
ARCELLX, INC.
SALE
13,6260Apr 28, 2026Apr 28, 2026View →
ACLX
ARCELLX, INC.
SALE
8,0110Apr 28, 2026Apr 28, 2026View →
DYN
DYNE THERAPEUTICS, INC.
SALEGRANT
Gift
53,6250Apr 24, 2026Apr 28, 2026View →
ACLX
ARCELLX, INC.
SALE10b5-1
10b5-1 plan
6,000$75.00$450.0K21,659Jan 20, 2026Jan 20, 2026View →
ACLX
ARCELLX, INC.
PURCHASE
6,000$6.28$37.7K27,659Jan 20, 2026Jan 20, 2026View →
ACLX
ARCELLX, INC.
SALE
6,00059,405Jan 20, 2026Jan 20, 2026View →
CBIO
CRESCENT BIOPHARMA, INC.
PURCHASEGRANT
Stock grant
9,0239,023Jun 23, 2025Jun 23, 2025View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,00035,000May 30, 2025Jun 3, 2025View →
ACLX
ARCELLX, INC.
PURCHASEGRANT
Stock grant
9,1749,174May 29, 2025May 30, 2025View →
VOR
VOR BIOPHARMA INC.
PURCHASEGRANT
Stock grant
30,00030,000May 22, 2025May 23, 2025View →
ACLX
ARCELLX, INC.
PURCHASEGRANT
Stock grant
8,0118,011May 28, 2024Jun 6, 2024View →
VOR
VOR BIOPHARMA INC.
PURCHASEGRANT
Stock grant
30,00030,000May 23, 2024May 28, 2024View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,13325,133May 22, 2024May 24, 2024View →
ACLX
ARCELLX, INC.
PURCHASEGRANT
Stock grant
11,45911,459Jun 14, 2023Jun 16, 2023View →
VOR
VOR BIOPHARMA INC.
PURCHASEGRANT
Stock grant
30,00030,000May 26, 2023Jun 2, 2023View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
24,90024,900May 24, 2023May 25, 2023View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
7,2227,222Jul 5, 2022Jul 6, 2022View →
VOR
VOR BIOPHARMA INC.
PURCHASEGRANT
Stock grant
16,91116,911Jun 14, 2022Jun 16, 2022View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,59619,596Jun 3, 2022Jun 6, 2022View →
ACLX
ARCELLX, INC.
SALE
21,6590Feb 8, 2022Feb 9, 2022View →
ACLX
ARCELLX, INC.
PURCHASE
21,65921,659Feb 8, 2022Feb 9, 2022View →
ACLX
ARCELLX, INC.
PURCHASEGRANT
Stock grant
61,53861,538Feb 3, 2022Feb 7, 2022View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,59619,596May 26, 2021May 27, 2021View →
VOR
VOR BIOPHARMA INC.
PURCHASEGRANT
Stock grant
16,90016,900Feb 5, 2021Feb 9, 2021View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
53,62553,625Sep 21, 2020Sep 23, 2020View →
DYN
DYNE THERAPEUTICS, INC.
SALE
177,8720Sep 21, 2020Sep 23, 2020View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASE
177,872$2.81$500.0K177,872Aug 7, 2020Sep 23, 2020View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,44414,444Jul 31, 2020Sep 23, 2020View →
DYN
DYNE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,15611,156Jul 31, 2020Sep 23, 2020View →
Other insiders · ACLX
Loading peer insiders…
About this filer
CIK 0001572000
ROLE
Director
PRIMARY
ACLX
COMPANIES
4
ACTIVE SINCE
Jul 2020
MARKETPEEL · /INSIDER/0001572000DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback